CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. EC50 value: 2.7 μM for NR2C and 2.8 μM for NR2D
靶点:
NMDAR
体外研究:
CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models. NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively). It has no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses.